Point72 Hong Kong LTD Ardelyx, Inc. Transaction History

Point72 Hong Kong LTD

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.65 - $1.18 $787 - $1,428	-1,211 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$0.86 - $1.7 $38,554 - $76,212	-44,831 Reduced 97.37%	1,211 $1,000
Q3 2021 Nov 15, 2021	BUY	$1.27 - $8.17 $58,473 - $376,163	46,042 New	46,042 $61,000
Q2 2021 Aug 16, 2021	SELL	$6.55 - $8.98 $9,582 - $13,137	-1,463 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$6.1 - $7.69 $244 - $307	-40 Reduced 2.66%	1,463 $10,000
Q4 2020 Feb 16, 2021	SELL	$5.05 - $7.1 $2,227 - $3,131	-441 Reduced 22.69%	1,503 $10,000
Q3 2020 Nov 16, 2020	BUY	$5.25 - $7.08 $10,206 - $13,763	1,944 New	1,944 $10,000
Q2 2020 Aug 14, 2020	SELL	$5.37 - $8.11 $15,524 - $23,446	-2,891 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$4.35 - $8.79 $5,180 - $10,468	1,191 Added 70.06%	2,891 $16,000
Q4 2019 Feb 14, 2020	BUY	$4.23 - $8.29 $7,191 - $14,092	1,700 New	1,700 $13,000
Q3 2018 Nov 14, 2018	SELL	$3.75 - $4.65 $3,285 - $4,073	-876 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$3.7 - $5.8 $3,241 - $5,080	876 New	876 $3,000

218

141M

1.08M

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $799M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.